Healthcare
hVIVO plc(OPORF)
Live Price
Offline$0.1096
+0.00% today
Window Change
+27.29%
Window
May 29, 2026 β Jun 18, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -25.4%
- EPS Growth
- -155.4%
- Dividend Yield
- 2.7%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars Β· May 29, 2026 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
hVIVO plc (OPORF) is a Healthcare stock with a market cap of $50.00M and listed on OTC. The stock last traded around $0.11 and up 27.3% across the available one-year price window (May 29, 2026 β Jun 18, 2026). Baseline metrics include revenue growth of -25.4%, EPS growth of -155.4%, a dividend yield of 2.7%. What stands out right now is revenue -25.4%, EPS -155.4%, free cash flow -287.9% with operating margin -13.1% and ROIC -11.1%. The dividend matters to the case here, with a current yield around 2.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OPORF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-25.4% vs +7.6% peer median
Operating Margin
Below sector median
-13.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 15, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -25.4% and EPS is at -155.4%, with operating margin around -13.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.7%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
OPORF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OPORF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OPORF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OPORF and SPY.
Company Overview
hVIVO plc
Other OTC
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preΒclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
- Leadership
- Yamin Mohammed Khan
- IPO Date
- Jun 5, 2020
- Employees
- 301
- Street Address
- 21 Plumbers Row
- Mailing
- London, E1 1EQ
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 7756 1300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 1.0
- Price/Book
- 1.3
Growth
- Revenue
- -25.4%
- EPS
- -155.4%
- Free Cash Flow
- -287.9%
Profitability
- Gross Margin
- -6.1%
- Operating Margin
- -13.1%
- Net Margin
- -12.5%
- ROE
- -14.7%
- ROIC
- -11.1%
Balance Sheet
- Debt/Equity
- 0.39
- Current Ratio
- 1.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.